Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

NCT01511874 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: ELIGARD 22.5mg

Sponsor

HanAll BioPharma Co., Ltd.